FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2328135220> ?p ?o ?g. }

• W2328135220 endingPage "26274" @default.
• W2328135220 startingPage "26259" @default.
• W2328135220 abstract "// Steven Kregel 1 , James L. Chen 2 , Westin Tom 5 , Venkatesh Krishnan 5 , Jacob Kach 3 , Hannah Brechka 1 , Tim B. Fessenden 1 , Masis Isikbay 3, 5 , Gladell P. Paner 4 , Russell Z. Szmulewitz 3, * , Donald J. Vander Griend 1, 5, * 1 Committee on Cancer Biology, The University of Chicago, Chicago, IL, USA 2 Department of Biomedical Informatics and Internal Medicine, The Ohio State University, Columbus, OH, USA 3 Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, IL, USA 4 Department of Pathology, The University of Chicago, Chicago, IL, USA 5 Department of Surgery, Section of Urology, The University of Chicago, Chicago, IL, USA * These authors contributed equally to this work Correspondence to: Donald J. Vander Griend, email: prostate@uchicago.edu Keywords: androgen receptor, prostate cancer, castration-resistance, enzalutamide Received: October 06, 2015      Accepted: March 13, 2016      Published: March 29, 2016 ABSTRACT Enzalutamide (MDV3100) is a second generation Androgen Receptor (AR) antagonist with proven efficacy in the treatment of castration resistant prostate cancer (CRPC). The majority of treated patients, however, develop resistance and disease progression and there is a critical need to identify novel targetable pathways mediating resistance. The purpose of this study was to develop and extensively characterize a series of enzalutamide-resistant prostate cancer cell lines. Four genetically distinct AR-positive and AR-pathway dependent prostate cancer cell lines (CWR-R1, LAPC-4, LNCaP, VCaP) were made resistant to enzalutamide by long-term culture (> 6 months) in enzalutamide. Extensive characterization of these lines documented divergent in vitro growth characteristics and AR pathway modulation. Enzalutamide-resistant LNCaP and CWR-R1 cells, but not LAPC-4 and VCAP cells, demonstrated increased castration-resistant and metastatic growth in vivo . Global gene expression analyses between short-term enzalutamide treated vs. enzalutamide-resistant cells identified both AR pathway and non-AR pathway associated changes that were restored upon acquisition of enzalutamide resistance. Further analyses revealed very few common gene expression changes between the four resistant cell lines. Thus, while AR-mediated pathways contribute in part to enzalutamide resistance, an unbiased approach across several cell lines demonstrates a greater contribution toward resistance via pleiotropic, non-AR mediated mechanisms." @default.
• W2328135220 created "2016-06-24" @default.
• W2328135220 creator A5037373285 @default.
• W2328135220 creator A5044034658 @default.
• W2328135220 creator A5044996624 @default.
• W2328135220 creator A5047066806 @default.
• W2328135220 creator A5058829655 @default.
• W2328135220 creator A5064568053 @default.
• W2328135220 creator A5070829983 @default.
• W2328135220 creator A5078252133 @default.
• W2328135220 creator A5082012240 @default.
• W2328135220 creator A5082988968 @default.
• W2328135220 creator A5085028695 @default.
• W2328135220 date "2016-03-29" @default.
• W2328135220 modified "2023-10-12" @default.
• W2328135220 title "Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer" @default.
• W2328135220 cites W1701091641 @default.
• W2328135220 cites W1962964452 @default.
• W2328135220 cites W1965674043 @default.
• W2328135220 cites W1967623316 @default.
• W2328135220 cites W1970833195 @default.
• W2328135220 cites W1976427653 @default.
• W2328135220 cites W1988319444 @default.
• W2328135220 cites W1990251608 @default.
• W2328135220 cites W1994406643 @default.
• W2328135220 cites W1995039837 @default.
• W2328135220 cites W1996956937 @default.
• W2328135220 cites W2010246016 @default.
• W2328135220 cites W2014751188 @default.
• W2328135220 cites W2022810442 @default.
• W2328135220 cites W2035397440 @default.
• W2328135220 cites W2037700362 @default.
• W2328135220 cites W2041997083 @default.
• W2328135220 cites W2063580912 @default.
• W2328135220 cites W2069736491 @default.
• W2328135220 cites W2079298594 @default.
• W2328135220 cites W2080748037 @default.
• W2328135220 cites W2082462837 @default.
• W2328135220 cites W2093585033 @default.
• W2328135220 cites W2094252220 @default.
• W2328135220 cites W2096643907 @default.
• W2328135220 cites W2097226696 @default.
• W2328135220 cites W2100465174 @default.
• W2328135220 cites W2104762821 @default.
• W2328135220 cites W2110841612 @default.
• W2328135220 cites W2113194416 @default.
• W2328135220 cites W2119816167 @default.
• W2328135220 cites W2120114069 @default.
• W2328135220 cites W2121846636 @default.
• W2328135220 cites W2124568178 @default.
• W2328135220 cites W2130189600 @default.
• W2328135220 cites W2133148545 @default.
• W2328135220 cites W2134988422 @default.
• W2328135220 cites W2136344158 @default.
• W2328135220 cites W2148643283 @default.
• W2328135220 cites W2154522534 @default.
• W2328135220 cites W2156923287 @default.
• W2328135220 cites W2333927480 @default.
• W2328135220 cites W4247126447 @default.
• W2328135220 cites W98260330 @default.
• W2328135220 doi "https://doi.org/10.18632/oncotarget.8456" @default.
• W2328135220 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5041979" @default.
• W2328135220 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27036029" @default.
• W2328135220 hasPublicationYear "2016" @default.
• W2328135220 type Work @default.
• W2328135220 sameAs 2328135220 @default.
• W2328135220 citedByCount "78" @default.
• W2328135220 countsByYear W23281352202016 @default.
• W2328135220 countsByYear W23281352202017 @default.
• W2328135220 countsByYear W23281352202018 @default.
• W2328135220 countsByYear W23281352202019 @default.
• W2328135220 countsByYear W23281352202020 @default.
• W2328135220 countsByYear W23281352202021 @default.
• W2328135220 countsByYear W23281352202022 @default.
• W2328135220 countsByYear W23281352202023 @default.
• W2328135220 crossrefType "journal-article" @default.
• W2328135220 hasAuthorship W2328135220A5037373285 @default.
• W2328135220 hasAuthorship W2328135220A5044034658 @default.
• W2328135220 hasAuthorship W2328135220A5044996624 @default.
• W2328135220 hasAuthorship W2328135220A5047066806 @default.
• W2328135220 hasAuthorship W2328135220A5058829655 @default.
• W2328135220 hasAuthorship W2328135220A5064568053 @default.
• W2328135220 hasAuthorship W2328135220A5070829983 @default.
• W2328135220 hasAuthorship W2328135220A5078252133 @default.
• W2328135220 hasAuthorship W2328135220A5082012240 @default.
• W2328135220 hasAuthorship W2328135220A5082988968 @default.
• W2328135220 hasAuthorship W2328135220A5085028695 @default.
• W2328135220 hasBestOaLocation W23281352201 @default.
• W2328135220 hasConcept C121608353 @default.
• W2328135220 hasConcept C126322002 @default.
• W2328135220 hasConcept C126894567 @default.
• W2328135220 hasConcept C134018914 @default.
• W2328135220 hasConcept C143998085 @default.
• W2328135220 hasConcept C170493617 @default.
• W2328135220 hasConcept C2776551883 @default.
• W2328135220 hasConcept C2776885963 @default.
• W2328135220 hasConcept C2777911890 @default.
• W2328135220 hasConcept C2780192828 @default.

• next